Diabetes Research and Clinical Practice
Volume 72, Issue 3 , Pages 265-270 , June 2006

Comparative efficacy of glimepiride and/or metformin with insulin in type 2 diabetes

  • Udaya M. Kabadi

      Affiliations

    • VA Medical Center, Phoenix, AZ, USA
    • University of Arizona, College of Medicine, Tucson, AZ, USA
    • University of Iowa Hospitals and Clinics, Iowa City, IA, USA
    • Corresponding Author InformationCorresponding author at: Roy and Lucille Carver College of Medicine, University of Iowa, 601 U.S. Highway 6 West, 6W27 VAMC, Iowa City, IA 52246, USA. Tel.: +1 319 338 0581x5212; fax: +1 319 339 7040.
    • ,
  • Mary Kabadi

      Affiliations

    • VA Medical Center, Phoenix, AZ, USA

Received 5 July 2005 ,Revised 19 October 2005 ,Accepted 27 October 2005.

References 

  1. Riddle M, Hart JS, Bouma DJ, Phillipson BE, Youker G. Efficacy of bedtime NPH insulin in treatment of secondary failure to glibenclamide. Diabetes Care. 1989;12:582–585
  2. Sontaniemi E. Insulin and sulfonylurea in the therapy of type 2 diabetes. Diabetes Res. Clin. Pract. 1990;8:243–251
  3. Simpson H, Sturley R, Stirling C, Reckless J. Combination of insulin with glipizide increases peripheral glucose disposal in secondary failure type 2 diabetic subjects. Diabetes Med. 1990;7:143–147
  4. Del Prato S, Vigili de Kreutzenberg S, Riccio A, Maifreni L, Duner E, Lisato G, et al. Partial recovery of insulin secretion and action after combined insulin–sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic subjects with secondary failure to oral agents. Diabetologia. 1990;33:688–695
  5. Groop L, Widen E. Treatment strategies for secondary sulfonylurea failure. Diabetes Metab. 1991;17:219–223
  6. Kabadi U, Kabadi M. Type II diabetic subjects with secondary failure: treatment with pre-breakfast mixed ultralente and regular insulin with a sulfonylurea. J. Fam. Pract. 1991;33:349–353
  7. Yki-Jarvinen H, Kauppila M, Kujansuue E, Lahti J, Marjanen T, Niskanen L, et al. Comparison of insulin regimens in subjects with non-insulin dependent diabetes mellitus. N. Engl. J. Med. 1992;329:1426–1433
  8. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea combination therapy in type 2 diabetes mellitus. Arch. Intern. Med. 1996;156:259–264
  9. Lindstrom T, Nystrom FH, Olsson AG, Arnqvist HJ. The lipoprotein differs during insulin treatment alone and combination therapy with insulin and sulfonylureas in subjects with type 2 diabetes mellitus. Diabetes Med. 1999;16:820–826
  10. Wright A, Felix Burden AC, Paisey RB, Cull CA, Holman RR. Sulfonylurea inadequacy. Diabetes Care. 2002;25:330–336
  11. Riddle MC, Schneider J. The glimepiride combination group. Beginning insulin treatment of obese subjects with evening 70/30 insulin plus glimepiride versus insulin alone. Diabetes Care. 1998;21:1052–1057
  12. Schwartz S, Raskin P, Fonesca V, Graveline J. Effect of troglitazone in insulin-treated subjects with type II diabetes mellitus. N. Engl. J. Med. 1998;338:861–866
  13. Buse JB, Gumbiner B, Mathias NP, Nelson DB, Faja BW, Whitcomb RW. Troglitazone use in insulin-treated type 2 diabetic subjects. Diabetes. 1999;48:1455–1461
  14. Yu JG, Kruszynska YT, Mulford MI, Olefsky JM. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic subjects. Diabetes. 1999;48:2414–2421
  15. Golay A, Guillet-Dauphine N, Fendel A, Juge C, Assal JP. The insulin-sparing effect of metformin in insulin-treated diabetic subjects. Diabetes Metab. Rev. 1995;11:S63–S67
  16. Giugliano D, Quatraro A, Consoli G, Minei A, Ceriello A, De Rosa N, et al. Metformin for obese, insulin-treated diabetic subjects: improvement in glycemic control and reduction of metabolic risk factors. Eur. J. Clin. Pharmacol. 1993;44:107–112
  17. Slama G. The insulin sparing effect of metformin in insulin-treated diabetic subjects. Diabetic Metab. 1991;7:241–243
  18. Chaudhuri A, Tomar R, Moharty P, Szudzik E, Bandyopadhyay A, Arian M, et al. The combination of insulin and metformin in treatment of non-insulin dependent diabetes mellitus. Endocr. Pract. 1998;4:259–267
  19. Kabadi U, Kabadi M. Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. Ann. Pharmacolther. 2003;37:1572–1576
  20. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J Rosiglitazone Clinical Trials Study Group. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Diabetes Care. 2001;24:1226–1232
  21. Rosenstock J, Einhor D, Hershon K, Glazer NB. Efficacy and safety of pioglitazone in type 2 diabetes: a randomized, placebo-controlled study in patients receiving stable insulin therapy. Int. J. Clin. Pract. 2002;56:251–257
  22. Yki-Jarvinen H, Ryysy L, Nikkila K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann. Intern. Med. 1999;130:389–396
  23. Strowig S, Aviles M, Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care. 2004;27:1577–1583
  24. Kabadi UM, O’Connell KM, Johnson J, Kabadi M. The effect of recurrent practice at home on the acceptability of capillary blood glucose readings. Diabetes Care. 1994;17:1110–1114
  25. Massi-Benedetti M, Herz M, Pfeiffer C. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Horm. Metab. Res. 1996;28:451–455
  26. Draeger E. Clinical profile of glimepiride. Diabetes Res. Clin. Pract. 1995;28:S139–S146
  27. Gonzales JU, Butron CD. Glimepiride its action on body weight and lipid profile in type II diabetes mellitus. Prospective clinical experiment in Latin-America. Tribuna Medica. 1999;84:151–158
  28. Holstien A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab. Res. Rev. 2001;17:467–473
  29. Korytkowski M, Thomas A, Reid L, Tedesco MB, Gooding WE, Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care. 2002;25:1607–1611
  30. Kabadi UM, Kabadi M. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. Clin. Ther. 2004;26:63–69
  31. Overkamp D, Volk A, Maerker E, Heide PE, Wahl HG, Rett K, et al. Accute effect of glimepiride on insulin-stimulated glucose metabolism in glucose-tolerant insulin-resistant offspring of patients with type 2 diabetes. Diabetes Care. 2002;25:2065–2073
  32. Janka HU, Plewe G, Riddle MC, Klieve-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial therapy for type 2 diabetes. Diabetes Care. 2005;28:252–259
  33. Standl E, Maxeiner S, Raptis S, Karimi-Anderesi Z, Schweitzer MA. Good glycemic control with flexibility in timing of basal insulin supply: a 24-week comparison of insulin glargine given once daily in the morning or at bedtime in combination with morning glimepiride. Diabetes Care. 2005;28:419–420
  34. Raskin P, Allen E, Hollender P, Lewin A, Gabbay RA, Hu P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–265
  35. J.K. Malone, L.F. Kerr, B.N. Campaigne, R.A. Sachson, J.H. Holcombe, Lispro Mixture-Glargine Study Group. Combined Therapy with Insulin Lispro Mix 75/35 Plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clinical Ther. 26 (2004) 2034–2044.
  36. A. Wright, A.C. Felix Burden, R.B. Paisley, C.A. Cull, R.R. Holman, U.K. Prospective Diabetes Study Group. Sulfonylurea Inadequacy; efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. prospective diabetes study, Diabetes Care 25 (2002) 330–336.
  37. UK Prospective Diabetes Study (UKPDS) Group. Intenstive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33), Lancet 12 (352) (1998) 837–853.
  38. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34), Lancet 12 (352) (1998) 854–865.

☆ Part of the data was presented at the Annual Meeting of American Diabetes Association held in San Francisco in June of 2002, and 18th International Diabetes Federation Congress held in Paris, France in August 2003.

PII: S0168-8227(05)00433-X

doi: 10.1016/j.diabres.2005.10.024

Diabetes Research and Clinical Practice
Volume 72, Issue 3 , Pages 265-270 , June 2006

Article Tools